Traveler’s diarrhea is the most common and most predictable travel-related illness. During a two-week trip, attack rates range from 30% to 70%, depending on destination and season. Recent estimates put the annual burden at 15 million to 20 million travelers to developing countries, although incidence during a two-week trip has declined from more than 65% two decades ago to about 10% to 40% in more recent assessments.
Contents
- How common is traveler’s diarrhea?
- Where and among whom is risk highest?
- Which pathogens are most often involved?
- What do global surveillance data show?
- How long does illness last and how severe can it be?
- What are the prevention and treatment statistics?
How common is traveler’s diarrhea?
The CDC Yellow Book 2026 describes attack rates of 30% to 70% among travelers over a two-week period. Destination and season account for much of that range. The illness is described by the CDC as the most predictable travel-related illness, and CDC Travelers’ Health likewise identifies it as the most common travel-related illness.
An FDA risk review published in 2018 estimated that 15 million to 20 million travelers to developing countries experience diarrhea each year. The same review expressed that annual burden as about 40,000 travelers per day. These are estimates of travelers affected, not a count of laboratory-confirmed infections.
The estimated overall incidence during a two-week trip changed over time in the FDA review: it fell from more than 65% two decades earlier to 10% to 40% in more recent estimates. That range is not directly interchangeable with the CDC Yellow Book’s 30% to 70% attack-rate range because the sources describe different periods and evidence bases.
Returned travelers also generate substantial clinical workload. In GeoSentinel data cited in the FDA risk review, acute and chronic diarrhea accounted for 335 of every 1,000 medical visits by returned travelers. About 10% of patients with traveler’s diarrhea seek medical care, and up to 3% require hospitalization.
Where and among whom is risk highest?
CDC Travelers’ Health lists Asia except Japan and South Korea, the Middle East, Africa, Mexico, and Central and South America among the highest-risk destinations. The destination categories are broad, so they should be treated as geographic risk groupings rather than a precise probability for every city, accommodation, or season.
The CDC Yellow Book 2026 reports that traveler’s diarrhea occurs equally in male and female travelers. It is more common in young adult travelers than in older travelers. A cohort of expatriates in Kathmandu averaged 3.2 episodes of traveler’s diarrhea per person during the first year, illustrating how repeated exposure can produce a substantially different experience from a single short vacation.
Several environmental conditions contribute to risk. The CDC identifies poor hygiene practices in local restaurants and deficiencies in sanitation and hygiene infrastructure as major contributors. Large numbers of people without plumbing or latrine access can increase environmental stool contamination. Frequent blackouts and poorly functioning refrigeration can also increase the chance of unsafe food storage.
The CDC notes that vaccines are not available in the United States for pathogens that commonly cause traveler’s diarrhea. Careful food and beverage choices can help lower risk, but the Yellow Book also reports that studies of food-and-water hygiene counseling may not show a decrease in diarrhea risk. That finding does not make food and beverage safety irrelevant; it means counseling results have not consistently translated into lower measured illness risk.
Which pathogens are most often involved?
The CDC Yellow Book 2026 estimates that bacteria account for at least 75% to 90% of cases. Intestinal viruses account for at least 10% to 25% of illnesses, while protozoal pathogens account for about 10% of diagnoses. These categories are estimates and should not be added mechanically as exact shares because their ranges and wording overlap.
Timing can provide a useful epidemiologic clue. Toxin-mediated illness usually resolves within 12 to 24 hours. Bacterial and viral pathogens usually have incubation periods of 6 to 96 hours. Protozoal illnesses usually have incubation periods of 1 to 2 weeks, so symptoms that begin well after arrival or after returning home can still fit a travel-related exposure.
The CDC’s 2024 Emerging Infectious Diseases report on the 2018–2023 Global Travelers’ Diarrhea study found country-specific differences in detected organisms:
| Location | Selected detected pathogen results |
|---|---|
| Peru | E. coli 67%; Campylobacter 20% |
| Nepal | E. coli 77%; Campylobacter 16% |
| Georgia | E. coli 75% |
| Honduras | E. coli 69% |
| Egypt | E. coli 82%; Salmonella 6% |
| Djibouti | E. coli 70%; Salmonella 6% |
These percentages are reported results for the listed study locations, not universal country-level prevalence estimates. In the same report, E. coli was found in 42% of cases during the 2013–2018 Global Travelers’ Diarrhea period and 72% during 2018–2023, showing a difference between the two surveillance periods.
What do global surveillance data show?
The CDC’s 2018–2023 Global Travelers’ Diarrhea study enrolled 512 participants across Honduras, Peru, Egypt, Djibouti, Nepal, and Georgia. Enrollment shares were 21% from Honduras, 3% from Peru, 3% from Egypt, 39% from Djibouti, 26% from Nepal, and 8% from Georgia. The average participant age was 34 years; the study population was 35% female, 59% male, and 6% of unidentified sex.
Among 106 ETEC isolates tested for colonization factors, CS3 was identified in 25%, CS21 in 25%, CS2 in 18%, and CS6 in 15%. CS17/19 was identified in 1%, and CS14 in 2%. CS5 and CS7 were not identified in any isolate. These measurements describe the tested isolates, not all cases of traveler’s diarrhea.
For another pathogen reference point, the CDC Yellow Book 2024 salmonellosis chapter reports that Salmonella infection is diagnosed in about 5 per 1,000 travelers who return with diarrhea. That statistic uses returned travelers with diarrhea as its reference group, rather than all travelers who took a trip.
How long does illness last and how severe can it be?
Acute traveler’s diarrhea is usually self-limited and lasts less than two weeks, according to the CDC Yellow Book 2026 post-travel diarrhea guidance. Persistent diarrhea is defined as lasting two weeks or longer. Giardia duodenalis is the most likely parasitic pathogen to cause persistent diarrhea, and untreated giardiasis can last for months even in immunocompetent hosts. Cryptosporidium infections are often asymptomatic or self-limited.
Severity is defined by functional impact. Mild diarrhea is tolerable and does not interfere with planned activities. Moderate diarrhea is distressing or interferes with planned activities. Severe diarrhea is incapacitating or completely prevents planned activities. All dysentery is considered severe traveler’s diarrhea.
Fluid and electrolyte losses occur during diarrhea, so replacement is important. Severe dehydration is unusual in otherwise healthy adults unless vomiting is prolonged. Post-infectious irritable bowel syndrome may occur in 3% to 17% of patients after traveler’s diarrhea, according to the FDA risk review. This is a reported range, not a prediction that every episode will produce persistent bowel symptoms.
What are the prevention and treatment statistics?
Bismuth subsalicylate reduces the incidence of traveler’s diarrhea by approximately 50% in the CDC Yellow Book 2026 summary. Its safety beyond three weeks has not been established. When handwashing is not possible, hand sanitizer should contain at least 60% alcohol. The CDC says available data are insufficient to recommend probiotics for traveler’s diarrhea prevention.
Prophylactic antibiotics are not recommended for most travelers. Fluoroquinolone resistance among Campylobacter and Shigella now limits prophylactic fluoroquinolone use, and antibiotics can increase the risk of colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae. These concerns help explain why routine antibiotic prevention is not the default approach.
For severe fluid loss, oral rehydration solution is typically prepared in 1 liter of boiled or treated water. The CDC lists loperamide as an option beginning with 4 mg, followed by 2 mg after each loose stool, with a maximum of 16 mg in 24 hours.
The CDC Yellow Book 2026 lists several antibiotic self-treatment regimens. Azithromycin may be given as 1,000 mg once or in divided doses, or 500 mg daily for three days. Ciprofloxacin options include 750 mg once or 500 mg twice daily for three days. Levofloxacin is listed at 500 mg once daily for one to three days. Rifamycin SV is listed at 388 mg twice daily for three days, and rifaximin at 200 mg three times daily for three days.
Antibiotic therapy can shorten bacterial traveler’s diarrhea by about one to two days. Rifaximin is approved for traveler’s diarrhea caused by noninvasive E. coli strains. Rifamycin SV was superior to placebo in two randomized clinical trials and noninferior to ciprofloxacin. Treatment choice should account for illness severity, suspected pathogen, resistance, and clinical contraindications rather than relying on a single statistic.